Dopaminergic Agonists and Muscarinic Antagonists Improve Lateralization in Hemiparkinsonian Rats in a Novel Exploratory Y-Maze

Journal of Pharmacology and Experimental Therapeutics

Volumn 309, Issue 2, 2004, Pages 737-744

  Nakagawa, Makoto ^a   Ohgoh, Makoto ^a   Nishizawa, Yukio ^a   Ogura, Hiroo ^a  

^a EISAI CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; APOMORPHINE; DIZOCILPINE; DOPAMINE RECEPTOR STIMULATING AGENT; IDAZOXAN; LEVODOPA; METHAMPHETAMINE; MUSCARINIC RECEPTOR BLOCKING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; OXIDOPAMINE; SCOPOLAMINE; TRIHEXYPHENIDYL;

AKINESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG EFFECT; DRUG MEGADOSE; LOCOMOTION; MALE; MAZE TEST; MUSCLE RIGIDITY; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; RAT; STRIATONIGRAL DEGENERATION; SYMPTOMATOLOGY; TREMOR;

ANIMALS; ANTIPARKINSON AGENTS; CHOLINERGIC ANTAGONISTS; DISEASE MODELS, ANIMAL; DIZOCILPINE MALEATE; DOPAMINE AGONISTS; FUNCTIONAL LATERALITY; LEVODOPA; MALE; MUSCARINIC ANTAGONISTS; OXIDOPAMINE; PARKINSON DISEASE; RATS; RATS, WISTAR;

EID: 2142754442     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.059519     Document Type: Article

References (40)

1. Bammer G (1982) Pharmacological investigations of neurotransmitter involvement in passive avoidance responding: a review and some new results. Neurosci Biobehav Rev 6:247-296.
2. Brefel-Courbon C, Thalamas C, Saint Paul HP, Senard J-M, Montastruc J-L, and Rascol O (1998) α2-Adrenoceptor antagonists: a new approach to Parkinson's disease? CNS Drugs 10:189-207.
3. 18F-dopa uptake in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. Ann Neurol 28:547-555.
4. 123I]β-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J Neural Transm Suppl 50:9-24.
5. Dalvi A and Ford B (1998) Antiparkinsonian agents: clinically significant drug interactions and adverse effects and their management. CNS Drugs 9:291-310.
6. Domino EF and Lisong NI (1998) Trihexyphenidyl interactions with the dopamine D1-selective receptor agonist SKF-82958 and the D2-selective receptor agonist N-0923 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced hemiparkinsonian monkeys. J Pharmacol Exp Ther 284:307-311.
7. Dunnett SB and Björklund A (1999) Prospects for new restorative and neuroprotective treatments in Parkinson's disease. Nature (Lond) 399:A32-A39.
8. Fink-Jensen A, Kristensen P, Shannon HE, Calligaro DO, Delapp NW, Whitesitt C, Ward JS, Thomsen C, Rasmusseen T, Sheardown MJ, et al. (1998) Muscarinic agonists exhibit functional dopamine antagonism in unilaterally 6-OHDA lesioned rats. Neuroreport 9:3481-3486.
9. Gerlach M and Riederer P (1996) Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J Neural Transm 103:987-1041.
10. Goldstein JM, Barnett A, and Malick JB (1975) The evaluation of anti-parkinson drugs on reserpine-induced rigidity in rats. Eur J Pharmacol 33:183-188.
11. Hornykiewicz O (1966) Dopamine (3-hydroxytyramine) and brain function. Pharmacol Rev 18:925-964.
12. Hornykiewicz O (1998) Biochemical aspects of Parkinson's disease. Neurology 51 (Suppl 2):S2-S9.
13. Kagaya T, Kajiwara A, Nagato S, Akasaka K, and Kubota A (1996) E2011, a novel, selective and reversible inhibitor of monoamine oxidase type A. J Pharmacol Exp Ther 278:243-251.
14. Kirik D, Rosenblad C, and Björklund A (1998) Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp Neurol 152: 259-277.
15. Kish SJ, Shannak K, and Hornykiewicz O (1988) Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease: pathophysiologic and clinical implications. N Engl J Med 318:876-880.
16. Konitsiotis S, Blanchet PJ, Verhagen L, Lamers E, and Chase TN (2000) AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. Neurology 54:1589-1595.
17. Kopin IJ (1993) The pharmacology of Parkinson's disease therapy: an update. Annu Rev Pharmacol Toxicol 32:467-495.
18. Marsden CD, Parkes JD, and Quinn N (1981) Fluctuations of disability in Parkinson's disease - clinical aspects, in Movement Disorders (Marsden CD and Fahn S eds) pp 96-122, Butterworth Scientific, London.
19. Molchan SE, Martinez RA, Hill JL, Weingartner HJ, Thompson K, Vitiello B, and Sunderland T (1992) Increased cognitive sensitivity to scopolamine with age and a perspective on the scopolamine model. Brain Res Rev 17:215-226.
20. Morelli M, Fenu S, Cozzolino A, Pinna A, Carta A, and Di Chiara G (1993) Blockade of muscarinic receptors potentiates D1 dependent turning behavior and c-fos expression in 6-hydroxydopamine-lesioned rats but does not influence D2 mediated responses. Neuroscience 53:673-678.
21. Mukhida K, Baker KA, Sadi D, and Mendez I (2001) Enhancement of sensorimotor behavioral recovery in hemiparkinsonian rats with intrastriatal, intranigral, and intrasubthalamic nucleus dopaminergic transplants. J Neurosci 21:3521-3530.
22. Ogura H, Kosasa T, Kuriya Y, and Yamanishi Y (2000) Donepezil, a centrally acting acetylcholinesterase inhibitor, alleviates learning deficits in hypocholinergic models in rats. Methods Find Exp Clin Pharmacol 22:89-95.
23. Olanow CW and Koller WC (1998) An algorithm (decision tree) for the management of Parkinson's disease: treatment guidelines. Neurology 50 (Suppl 3):S1-S57.
24. Olanow CW, Watts RL, and Koller WC (2001) An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 56 (Suppl 5):S1-S88.
25. Olsson M, Nikkhah G, Bentlage C, and Björklund A (1995) Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. J Neurosci 15:3863-3875.
26. Paxinos G and Watson C (1996) The Rat Brain in Stereotaxic Coordinates, 3rd ed, Academic Press, San Diego.
27. Poewe W (1998) Should treatment of Parkinson's disease be started with a dopamine agonist? Neurology 51 (Suppl 2):S21-S24.
28. Roberts DCs, Zis AP, and Fibiger HC (1975) Ascending catecholamine pathways and amphetamine-induced locomotor activity: importance of dopamine and apparent non-involvement of norepinephrine. Brain Res 93:441-454.
29. Schallert T, De Ryck M, Whishaw IQ, Ramirez VD, and Teitelbaum P (1979) Excessive bracing reactions and their control by atropine and L-dopa in an animal analog of parkinsonism. Exp Neurol 64:33-43.
30. Schallert T, Whishaw IQ, Ramirez VD, and Teitelbaum P (1978) Compulsive, abnormal walking caused by anticholinergics in akinetic, 6-hydroxydopamine-treated rats. Science (Wash DC) 199:1461-1463.
31. Schwarting RK and Huston JP (1996) The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog Neurobiol (Oxford) 50:275-331.
32. Silver DE and Ruggieri S (1998) Initiating therapy for Parkinson's disease. Neurology 50 (Suppl 6):S18-S22.
33. Standaert DG and Young AB (1995) Treatment of central nervous system degenerative disorders, in Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th ed. (Hardman JG, Molinoff PB, Ruddon RW, and Goodman Gilman A eds) pp 503-519, McGraw-Hill Companies, New York.
34. Steece-Collier K, Chambers LK, Jaw-Tsai SS, Menniti FS, and Greenamyre JT (2000) Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-D-aspartate receptors. Exp Neurol 163:239-243.
35. Takikawa S, Dhawan V, Chaly T, Robeson W, Dahl R, Zanzi I, Mandel F, Spetsieris P, and Eidelberg D (1994) Input functions for 6-[fluorine-18]fluorodopa quantitation in parkinsonism: comparative studies and clinical correlations. J Nucl Med 35:955-963.
36. Ungerstedt U and Arbuthnott GW (1970) Quantitative recording of rotational behavior in rats after 6-hydroxydopamine lesions of the nigrostriatal dopamine system. Brain Res 24:485-493.
37. Verhagen Metman L, Del Dotto P, Natté R, van den Munckhof P, and Chase TN (1998) Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease. Neurology 51:203-206.
38. Watts RL (1997) The role of dopamine agonists in early Parkinson's disease. Neurology 49 (Suppl 1):S34-S48.
39. Wichmann T and DeLong MR (1993) Pathophysiology of Parkinsonian motor abnormalities, in Advances in Neurology, Vol 60: Parkinson's Disease: from Basic Research to Treatment (Narabayashi H, Nagatsu T, Yanagisawa N, and Mizuno Y eds) pp 53-61 Raven Press, New York.
40. Williams BO and Carlyle D (1979) Levodopa/benserazide ('Madopar') combination therapy in elderly patients with parkinsonism. Curr Med Res Opin 6:1-7.